Claris Lifesciences hits record high on sale of injectables biz to Baxter
The stock surged 20% to Rs 430, also its record high on the BSE in opening deal.
SI Reporter Mumbai Claris Lifesciences has surged 20% to Rs 430, also its record high on the BSE in opening deals, after the company said it has entered into a definitive agreement with US-based Baxter International Inc. to sell its wholly owned subsidiary Claris Injectables for approximately $625 million (Rs 4,237 crore).
The injectables business comprises about 78% of Claris Lifescience's business for year ending March 31, 2016, the remaining coming from pass-through sales of Claris-Otsuka.
Commenting on the deal Handa said, "We have been focused on the injectables segment and have created a world class integrated business model from research to marketing and a platform with high entry barrier specialty products and technology, R&D capability and world-class manufacturing infrastructure with a quality team having best in class knowledge."
At 09:25 am; the stock was up 10% at Rs 396 on the BSE as compared to 0.07% rise in the S&P BSE Sensex. The trading volumes on the counter jumped more than three-fold with around one million shares changed hands so far against an average 342,000 shares that were traded daily in past two weeks on the BSE.